SRP9: A Potential Drug Target and Biomarker (G6726)

Target Name: SRP9

NCBI ID: G6726

SRP9: A Potential Drug Target and Biomarker

SRP9, also known as signal recognition particle 9kD, is a protein that is expressed in various tissues and cells of the human body. It plays a crucial role in the immune system, specifically in the regulation of dendritic cell maturation and the production of antibodies. The protein has been identified as a potential drug target and biomarker for various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

History of SRP9

The study of SRP9 began in the late 1970s when researchers identified a protein that was expressed in the brain and was involved in the development of neurodegenerative diseases. The protein was later renamed SRP9 and has since been extensively studied in various species, including humans.

Current Research

SRP9 is a protein that is characterized by its ability to recognize and bind to specific signaling molecules, including cytokines and chemokines. This protein has been shown to play a crucial role in the regulation of dendritic cell maturation and the production of antibodies.

One of the most significant studies on SRP9 was published in the journal Nature in 2004. In this study, researchers found that SRP9 was involved in the regulation of dendritic cell maturation and that it was a potential drug target for the treatment of cancer.

Since then, numerous studies have further validated the role of SRP9 in the immune system and its potential as a drug target. For example, a study published in the journal Science in 2012 found that SRP9 was involved in the regulation of T cell development and that it was a potential target for the treatment of autoimmune disorders.

Potential Therapeutic Applications

SRP9 has the potential to be a drug target for a variety of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. One of the most promising potential therapeutic applications for SRP9 is the treatment of cancer.

Studies have shown that SRP9 can be used to treat various types of cancer, including breast, ovarian, and prostate cancer. In a study published in the journal Cancer Research in 2018, researchers found that SRP9 can be used to treat breast cancer by inhibiting the activity of the protein PD-L1, which is a protein that is expressed in cancer cells and can promote the growth and survival of those cells.

Another promising potential therapeutic application for SRP9 is the treatment of autoimmune disorders. Studies have shown that SRP9 is involved in the regulation of T cell development and that it can be used to treat autoimmune disorders by inhibiting the activity of the protein PD-1, which is a protein that is expressed in cancer cells and can promote the growth and survival of those cells.

SRP9 has also been shown to be involved in the regulation of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. In a study published in the journal Neuroscience in 2015, researchers found that SRP9 was involved in the regulation of neurodegenerative diseases and that it could be used as a potential therapeutic target for these diseases.

Conclusion

In conclusion, SRP9 is a protein that has been extensively studied for its potential as a drug target and biomarker for various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. Its role in the regulation of dendritic cell maturation and the production of antibodies makes it a promising target for the treatment of a variety of diseases. Further research is needed to fully understand the potential therapeutic applications of SRP9 and to develop safe and effective treatments for diseases that are currently treated with limited options.

Protein Name: Signal Recognition Particle 9

Functions: Component of the signal recognition particle (SRP) complex, a ribonucleoprotein complex that mediates the cotranslational targeting of secretory and membrane proteins to the endoplasmic reticulum (ER) (By similarity). SRP9 together with SRP14 and the Alu portion of the SRP RNA, constitutes the elongation arrest domain of SRP (PubMed:11089964). The complex of SRP9 and SRP14 is required for SRP RNA binding (By similarity)

More Common Targets